Compositions and methods for achieving hemostasis. Hemostatic compositions comprise a phospholipid, and optionally, an anti-infective agent. The hemostatic composition can be administered to a bleeding bone to achieve hemostasis.

The present application provides rapid-gelling, sprayable hyaluronic-acid based compositions, kits, related methods, precursor formulations, and uses thereof.

The present invention relates to an implant (10) comprising: -a substrate (1) the surface of which comprising oxidized cellulose, said oxidized cellulose having a degree of oxidation ranging from 0.0 to 1, and -a multilayer coating covering said substrate, said multilayer coating comprising at least a first layer (2) adjacent said substrate, said first layer being formed of chitosan, and a second layer (3) adjacent said first layer, said second layer being formed of oxidized cellulose having a degree of oxidation ranging from 0.5 to 1. The invention further relates to a method for preparing such an implant.

Adhesive compositions and patches, and associated systems, kits, and methods, are generally described. Certain of the adhesive compositions and patches can be used to treat tissues (e.g., in hemostatic or other tissue treatment applications), according to certain embodiments.

The present disclosure belongs to the technical field of hemostatic materials, and specifically relates to a degradable hemostatic sponge and a preparation method and use thereof, and a degradable drug-loaded hemostatic sponge. The degradable hemostatic sponge provided by the present disclosure is prepared from raw materials including a crosslinking-modified starch and a cellulose through freeze-drying, where a mass ratio of the crosslinking-modified starch to the cellulose is (0.2-5):1. The degradable hemostatic sponge provided by the present disclosure has a high water-absorbing rate and a large water-absorbing capacity, shows a high support strength and a long support time after water absorption, and is made from plant-derived raw materials and thus may be completely biodegraded. The degradable drug-loaded starch hemostatic sponge provided by the present disclosure has a drug-loaded coating attached to a surface of the sponge, where the drug is slowly released while a support is maintained.

The invention relates to porous absorbent Composite Material, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides a hydrophilic Self-Dispersive, fragmentable and Bio-Absorbable Porous Composite foams, suitable for packing antrum or other cavities of the body, comprising of composite of polymers, which polymer preferably comprises —C(O)—O—; NH2/3+; —OH; —CH2OCH2C(O)O— groups as functional or —CH—O— (e.g. C2H4O; C6H10O5; C6H8O6); —CH—N—O— (e.g. C8H13NO5); O—C—C— (e.g. O—CH2-CH2); —C(O)N— groups in the backbone of the polymers e.g. gelatin, chitosan, collagen, alginate, polyvinyl alcohol, polyethylene glycol, keratin, cellulose.

The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.

Combination cellulose materials and methods of making and using these materials. The combination material includes a first cellulosic material and a second cellulosic material.

The present disclosure provides compositions including self-degrading alginate particles comprising alginate, alginate lyase, and divalent metal ions. The present disclosure also provides methods of making compositions including self-degrading alginate particles comprising alginate, alginate lyase, and divalent metal ions. The present disclosure also provides methods of inducing an embolism in a subject in thereof, and syringes containing the compositions of the present disclosure for use in the methods thereof.

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.